Efficacy and Safety of SGLT2 Inhibitors and GLP ‐1 Receptor Agonists on Ventricular Arrhythmias and Cardiovascular Events: A Disease‐Stratified Network Meta‐Analysis
Pooled result · VA riskResult — go to the resultOdds ratio 0.31 95% CI 0.11–0.86Authors' conclusion
SGLT2 inhibitors consistently reduced HHF risk across the HF and T2DM networks and selected agents showed mortality benefits in clinically relevant populations. Empagliflozin showed an exploratory signal for lower VA risk in the T2DM network
Study context
- Population
- Patients with T2D and/or heart failure (HF) in RCTs
- Participants
- 140,156 patients32 RCTs
- Comparison
- Individual SGLT2i and GLP-1 RA vs each other and comparators
- Outcome
- Ventricular arrhythmias (VAs)
Methodological detailsdisease-stratified (HF and T2D networks), Four databases searched from inception through May 16, 2026, Nine outcomes evaluated
- Disease-stratified (HF and T2D networks)
- Four databases searched from inception through May 16, 2026
- Nine outcomes evaluated
Pooled result
VA risk
Odds ratio
0.31
95% CI 0.11–0.86
Individual SGLT2i and GLP-1 RAvs each other and comparators (largely placebo)
OR 0.31 (95% CI 0.11–0.86)
As reported in the abstract
Further pooled results
CV and all-cause mortality
- Dapagliflozin (HF network) and empagliflozin and liraglutide (T2D network) associated with lower CV and all-cause mortality
Hospitalization for HF
- SGLT2i consistently reduced hospitalization for heart failure (HHF) across both networks
Treatment rankings
- Networks largely placebo-centred without closed loops; rankings incl. P-score exploratory, not head-to-head evidence
Safety
Safety outcomes
- Dapagliflozin associated with lower AKI risk
- Albiglutide and liraglutide associated with lower hypoglycemia risk
- No statistically significant increase in DKA risk for empagliflozin
- Semaglutide fracture signal should be interpreted cautiously
- Sparse events; non-uniform adverse-event reporting across trials
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Efficacy and Safety of SGLT2 Inhibitors and GLP ‐1 Receptor Agonists on Ventricular Arrhythmias and Cardiovascular Events: A Disease‐Stratified Network Meta‐Analysis. Diabetes Obes Metab. Published 9 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →